Research article · 31 Aug 2020
Conference abstractPublished 10 Aug 2015
Intentional medication errors: Off-label use?
DADA Consultancy, Netherlands
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
To obtain a marketing authorisation (MA), companies are expected to evaluate the safe use of their medicinal product. In the risk management plan, dedicated sections address medication errors and off-label use; two sides of the same coin: the authorized product information guidance is not followed, either inadvertently (in error) or intentionally. Several initiatives are currently taking place to monitor medication errors, e.g. to develop a medication error SMQ, and the EMA has published good practice guides on coding and reporting, and on risk minimization and prevention. The balancing line between product usage that categorizes as medication errors versus off-label use is thin, and may be drawn differently by different MAHs, also depending on the authorized indications for their specific products. How often is it clear from the reported information that the “off-label” administration indeed occurred intentionally? How to code reports where a patient intentionally takes a product for longer than is written in the product information? Also, the same active substance, usually the level on which signal detection activities occur, can be authorised for multiple indications. This means that if signalling activities occur by different stakeholders, different results will be obtained. Finally, where the concept of medication errors includes an unintended error or failure in the drug treatment process, the concept of off-label refers to an intention to not use the product according to the authorised indication. How should this be managed?
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 26 Aug 2020
The Logic of Science and the Fallacies of Popular Medical Belief: Off-Label Uses of Existing Pharmaceuticals in COVID-19
Short communication · 20 Jul 2016
Off-label use of medical devices in pediatric interventional cardiology: prerogative or necessity?
Article · 29 Mar 2024
Ensuring Pharmacovigilance for Off-Label and Compounding Medications
Article · 11 Feb 2026
Off-Label Use of Vonoprazan and Mosapride for Management of Gastroesophageal Reflux in a Dog with Megaesophagus
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Angela van der Salm”
